MONDAY, Oct. 15, 2018 — Despite some parents’fears, girls who get vaccinated against human papillomavirus (HPV) do not see it as permission to have sex, a new study finds.
HPV is a sexually transmitted infection that can cause genital warts and…
Anogenital warts are the second most common sexually transmitted infection diagnosed in sexual health services in England. About 90% of genital warts are caused by human papillomavirus (HPV) types 6 or 11, and…
We present the case of a 77-year-old Caucasian male with enormous genital warts of the penis, scrotum, groins and anus. Lesions were excised by electrosurgery. The histological examination revealed Condylomata gigantea as well as an invasive perianal squamous cell carcinoma. Mucosal “low-risk” HPV type 6 was detected. The patient had a history of an immunosuppressing disease. During the 4-year follow-up, multiple relapses occurred. Thus, particularly in immunosuppressed patients, early prophylactic HPV vaccination seems to be indicated for use in the prevention of HPV-assoc iated mutilating and life-threatening…
Human papillomavirus (HPV) is the most common sexually transmitted infection, with at least half of sexually active people contracting the virus—a leading etiology for genital warts and anal, cervical, laryngeal, penile, vaginal, and vulvar cancers. Research suggests HPV is higher among U.S. military personnel than in U.S. civilian populations and can result in significant morbidity or complications and limit U.S. military’s duties or deployable status.
The aim of the study was to identify determinants of HPV vaccination among U.S. Navy personnel.
Participants (N = 233) rec…
The estimated prevalence of genital HPV DNA in the US male population is 2.9%. This burden of disease could potentially be lowered with increased usage of quadrivalent and nonavalent vaccinations.
Women vaccinated at an older (≥19 years) age may be less protected against AGWs, particularly if sexually active before vaccine administration. Further efforts should be targeted at increasing vaccine uptake among preadolescents before the initiation of sexual activity.
This study uses a large amount of national data to give us an idea about which groups of people have the greatest risk of carrying potentially cancer-causing oral HPV .
But while oral HPV may increase people’s risk of mouth and throat cancers, the actual number who would go on to develop cancer is extremely small.
This study has limitations, which are worth bearing in mind:
It only looked at whether people had oral HPV at a single point in time. This makes it difficult to know at what point they became infected and how much this could be down to other risk factors such as smoking, oral sex and number of partne…
Conclusions: Overall, a high rate of subsequent EGW episodes was observed in this high-risk population, despite high treatment rates and improvement in high-risk sexual behavior. These data, assessed in a prevaccination Québec health care system, may be compared with future EGW rates to assess the impact of a governmentally-funded HPV vaccination program.
Follow me on Twitter @RobShmerling
Did you know certain viruses can cause cancer? Two common examples include hepatitis C (which is linked with liver cancer) and human papilloma virus (HPV, which causes cervical cancer). The discovery of these virus-cancer connections is particularly important, because if a vaccine can prevent these viral infections it may also prevent cancer. And there is preliminary evidence that the HPV vaccine is making this happen. More on that in a moment.
What is HPV?
HPV is a group of viruses that may cause warts (papillomas) and a variety of cancers, including those involving the throat, rect…
The objective was to study real-life benefit of opportunistic HPV vaccination on age and gender specific incidence of genital warts.
METHODS: We performed a register-based population cohort study from publicly funded health-care provider in Israel. The incidence of genital warts was assessed during three time frame intervals: 2006-2008 (pre-vaccination effect period) 2009-2012 (early post-vaccination effect period) and 2013-2015 (late post-vaccination effect period), with an average annual number of members of 1,765,481, 1,906,774 and 2,042,678 in the years 2006-2008, 2009-2012 and 2013-2015, respectively.
Conclusions: Based on the evidence reviewed, NACI issued new recommendations for the use of HPV9 vaccine with a 2-dose immunization schedule at 0, 6-12 months in young females and males and updated the grade of evidence for the use of HPV vaccines in immunocompromised populations.
PMID: 29770079 [PubMed]